Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y Smith

Showing results (561-570 of 594) with videos related to

Pageof 60
Sort By:
Frontiers in Psychology|July 10, 2023
Balancing benefits and risks in lung cancer therapies: patient preferences for lung cancer treatment alternativesSerena Oliveri, Lucilla Lanzoni, Jorien Veldwijk, et al.
The Lancet. HIV|October 17, 2021
Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR studyChloe Orkin, Enrique Bernal Morell, Darrell H S Tan, et al.
Trials|April 16, 2015
Comparative effectiveness of home blood pressure telemonitoring (HBPTM) plus nurse case management versus HBPTM alone among Black and Hispanic stroke survivors: study protocol for a randomized controlled trialTanya M Spruill, Olajide Williams, Jeanne A Teresi, et al.
American Journal of Clinical Pathology|May 6, 2025
Biomarkers of response to antibody-drug conjugates (TROP2 and nectin-4) and the immune microenvironment (NKG7, PD-L1, and B7-H3) in penile squamous cell carcinomaBurak Tekin, John C Cheville, Fabrice Lucien, et al.
The Lancet. Infectious Diseases|July 24, 2015
Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trialDavid A Margolis, Cynthia C Brinson, Graham H R Smith, et al.
JAMA Neurology|October 17, 2018
Association of Bilateral Salpingo-Oophorectomy Before Menopause Onset With Medial Temporal Lobe NeurodegenerationBurcu Zeydan, Nirubol Tosakulwong, Christopher G Schwarz, et al.
AIDS (London, England)|September 17, 2021
Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infectionPedro Cahn, Juan Sierra Madero, José R Arribas, et al.
The Lancet. HIV|May 27, 2017
Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trialMartin Markowitz, Ian Frank, Robert M Grant, et al.
AIDS (London, England)|July 14, 2021
Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatmentSusan Swindells, Thomas Lutz, Lelanie Van Zyl, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 14, 2019
Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical TrialsPedro Cahn, Juan Sierra Madero, José R Arribas, et al.
Pageof 60

Showing results (561-570 of 594) with videos related to

Sort By:
Pageof 60
Frontiers in Psychology|July 10, 2023
Balancing benefits and risks in lung cancer therapies: patient preferences for lung cancer treatment alternativesSerena Oliveri, Lucilla Lanzoni, Jorien Veldwijk, et al.
The Lancet. HIV|October 17, 2021
Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR studyChloe Orkin, Enrique Bernal Morell, Darrell H S Tan, et al.
Trials|April 16, 2015
Comparative effectiveness of home blood pressure telemonitoring (HBPTM) plus nurse case management versus HBPTM alone among Black and Hispanic stroke survivors: study protocol for a randomized controlled trialTanya M Spruill, Olajide Williams, Jeanne A Teresi, et al.
American Journal of Clinical Pathology|May 6, 2025
Biomarkers of response to antibody-drug conjugates (TROP2 and nectin-4) and the immune microenvironment (NKG7, PD-L1, and B7-H3) in penile squamous cell carcinomaBurak Tekin, John C Cheville, Fabrice Lucien, et al.
The Lancet. Infectious Diseases|July 24, 2015
Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trialDavid A Margolis, Cynthia C Brinson, Graham H R Smith, et al.
JAMA Neurology|October 17, 2018
Association of Bilateral Salpingo-Oophorectomy Before Menopause Onset With Medial Temporal Lobe NeurodegenerationBurcu Zeydan, Nirubol Tosakulwong, Christopher G Schwarz, et al.
AIDS (London, England)|September 17, 2021
Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infectionPedro Cahn, Juan Sierra Madero, José R Arribas, et al.
The Lancet. HIV|May 27, 2017
Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trialMartin Markowitz, Ian Frank, Robert M Grant, et al.
AIDS (London, England)|July 14, 2021
Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatmentSusan Swindells, Thomas Lutz, Lelanie Van Zyl, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|December 14, 2019
Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical TrialsPedro Cahn, Juan Sierra Madero, José R Arribas, et al.
Pageof 60